Yuji Uehara

Dr. Yuji Uehara

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2022 in Thoracic Cancer
Verified
Journal Article
Open access
YUYuji Uehara
Yuji Uehara
KWKageaki Watanabe
Kageaki Watanabe
THTaiki Hakozaki
Taiki Hakozaki
MYMakiko Yomota
Makiko Yomota
YHYukio Hosomi
Yukio Hosomi
Background: In patients with non‐small cell lung cancer (NSCLC) harboring driver alterations, the efficacy of immune checkpoint inhibitors (ICIs) remains uncertain. Our study aimed to examine the first‐line ICI efficacy in patients with NSCLC harboring KRAS, MET, FGFR, RET, BRAF, and HER2 alterations in a real‐world setting.Methods: This single‐center, retrospective cohort study included patients with advanced NSCLC harboring KRAS, MET, FGFR, RET, BRAF, HER2 alterations or driver‐negative, and were treated with first‐line ICI therapy. Best overall response, progression‐free survival (PFS), and overall survival (OS) were evaluated.Results: Seventy‐eight patients with NSCLC were included (median age, 72 years): 67% were men, 15% were never‐smokers, and 83% had adenocarcinoma. The driver alterations involved KRAS (n = 21), MET (n = 6), FGFR (n = 3), RET (n = 2), BRAF (n = 2), HER2 (n = 1), and driver‐negative (n = 43). The partial responses for KRAS, MET, FGFR, RET, BRAF, HER2, and driver‐negative were 57%, 50%, 100%, 50%, 100%, 0%, and 47%, respectively. The median PFS (months) was 16.2 (95% confidence interval [CI]: 6.3– not reached [NR]) for KRAS, 2.8 (95% CI: 2.7–NR) for MET, 11.7 (95% CI: 5.9–NR) for other alterations (FGFR, RET, BRAF, and HER2), and 10.0 (95% CI: 3.7–14.3) for driver‐negative, respectively. The median OS (months) was 31.3 (95% CI: 9.0–NR) for KRAS, not reached for MET, 23.5 (95% CI: 18.3–NR) for other alterations, and 21.1 (95% CI: 15.2–NR) for driver‐negative, respectively.Conclusions: The benefit of the first‐line ICI was similar in advanced NSCLC regardless of the driver alterations, except for MET alterations.

5 March 2024 in JTO Clinical and Research Reports
Verified
Journal Article
Open access
THTsuyoshi Hirata
Tsuyoshi Hirata
YUYuji Uehara
Yuji Uehara
THTaiki Hakozaki
Taiki Hakozaki
TKTakayuki Kobayashi
Takayuki Kobayashi
YTYuto Terashima
Yuto Terashima
YHYukio Hosomi
Yukio Hosomi
Previous studies reported an association between immune checkpoint inhibitor infusion timing and the treatment effect in metastatic NSCLC. The present study assessed the association between durvalumab infusion timing and survival outcomes in patients with locally advanced NSCLC. Patients receiving durvalumab after chemoradiotherapy for locally advanced NSCLC at a single institution were retrospectively analyzed, and the association of the proportion of durvalumab infusions greater than or equal to 20% versus less than 20% after 3 PM with progression-free survival (PFS) and overall survival was assessed. A total of 82 patients were included, with a median age of 69 years (interquartile range, 62–74 years); of these, 67 patients (82%) were of male sex, and 78 patients (95%) had a history of smoking. The median number of durvalumab infusions per patient was 16 (interquartile range, 8–24). Patients with at least 20% of their durvalumab infusions after 3 PM (n = 12/82, 15%) had a significantly shorter PFS than those who did not (median: 7.4 mo versus not available [NA]; hazard ratio [HR], 2.43; 95% confidence interval [CI]: 1.11–5.34, p = 0.027), whereas overall survival was shorter among the former compared with the latter group (median: 22.4 versus NA; HR, 1.80; 95% CI: 0.73–4.42, p = 0.20). In addition, both backward stepwise multivariable analysis and propensity score–matching analysis revealed that receiving at least 20% of durvalumab infusions after 3 PM was significantly associated with worse PFS (HR, 2.54; 95% CI: 1.03–5.67, p = 0.047; and HR, 4.64; 95% CI: 1.95–11.04; p < 0.001, respectively). The time of day of durvalumab infusions may impact survival outcomes in patients with locally advanced NSCLC.

13 March 2015 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
MKMasato Kobayashi
Masato Kobayashi
SKShiori Kuroki
Shiori Kuroki
YTYu Tanaka
Yu Tanaka
YMYukari Moriya
Yukari Moriya
YKYukari Kozutumi
Yukari Kozutumi
MBMakoto Bonkobara
Makoto Bonkobara

15 June 2023 in JTO Clinical and Research Reports
Verified
Journal Article
Open access
TKTakayuki Kobayashi
Takayuki Kobayashi
YUYuji Uehara
Yuji Uehara
KWKageaki Watanabe
Kageaki Watanabe
THTsunekazu Hishima
Tsunekazu Hishima
YHYukio Hosomi
Yukio Hosomi
ALK-positive large-cell neuroendocrine carcinoma (LCNEC) is an exceptionally rare form of lung cancer. The efficacy of ALK inhibitors in treating ALK-positive LCNEC remains unclear. Here, we report a case of ALK-positive LCNEC of the lung, which revealed a sustained clinical benefit (24+ mo of overall survival) after treatment with sequential ALK inhibitors and local therapies. This remarkable improvement in survival underscores the importance of testing metastatic LCNEC for biomarkers, such as ALK rearrangement, using immunohistochemistry or next-generation sequencing, especially in younger patients.

4 August 2024 in Cancer Communications
Verified
Journal Article
Open access
YUYuji Uehara
Yuji Uehara
SKShumei Kato
Shumei Kato
DNDaisuke Nishizaki
Daisuke Nishizaki
HMHirotaka Miyashita
Hirotaka Miyashita
SLSuzanna Lee
Suzanna Lee
RKRazelle Kurzrock
Razelle Kurzrock

3 November 2025 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
YUYuji Uehara
Yuji Uehara
DNDaisuke Nishizaki
Daisuke Nishizaki
YFYu Fujiwara
Yu Fujiwara
HMHirotaka Miyashita
Hirotaka Miyashita
SLSuzanna Lee
Suzanna Lee
RKRazelle Kurzrock
Razelle Kurzrock
Background: CD40 is a T-cell co-stimulatory receptor targeted by next-generation immunotherapies. We conducted a pan-cancer transcriptome analysis of CD40, its ligand, and related immune markers to evaluate co-expression patterns and clinical outcomes. Methods: We analyzed transcriptome data for CD40, its ligand, and other common checkpoints and co-stimulators (PD-1, PD-L1, PD-L2, CTLA-4, LAG-3, ICOS, CD27, CD28, OX40, and GITR). RNA expression was classified as high (75–100th percentile), moderate (25–74th), or low (0–24th) against a reference population of 735 previously tested solid tumors. Results: Of 514 patients, 114 (22%) showed high, 247 (48%) moderate, and 153 (30%) low CD40 RNA expression. High CD40 expression was most frequent in liver and bile duct (42%), pancreatic (42%), and ovarian (40%) cancers. Both high CD40 and low–moderate CD40 ligand expression—potentially conducive to CD40 agonist therapy—was most frequent in ovarian (33%) and pancreatic (24%) cancer. In both UCSD (N = 514) and TCGA (N = 10,953) cohorts, high CD40 expression significantly correlated with high CD28 and GITR. High CD40 RNA levels were not prognostic for overall survival (OS) from metastatic disease ( P = 0.2) (n = 272 immune checkpoint inhibitor (ICI)-naïve patients). High CD40 expression correlated with longer OS from immunotherapy initiation (n = 217 ICI-treated patients; P = 0.04, univariable analysis), but not multivariable analysis, suggesting it may not be an independent predictive biomarker. Conclusion: High CD40 expression correlated with liver and bile duct, pancreatic, and ovarian cancers, as well as with CD28 and GITR transcripts. Immune marker co-expression in individual patients merits further exploration for the development of CD40-based and other immunotherapy interventions.